Oriel Therapeutics Inc.
http://www.orieltherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oriel Therapeutics Inc.
Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.
Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.
Deals Shaping the Medical Industry (05/2010)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Start-Up Previews (2/04)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Rediscovering Existing Drugs, features profiles of Ascend Therapeutics Inc., Ocularis Pharma Inc. and Oriel Therapeutics Inc. Plus these Start-Ups Across Health Care: Exagen Diagnostics Inc., Piedmont Pharmaceuticals LLC, Protein Forest Inc., Proteus Biomedical Inc. and Xilas Medical Inc.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice